drugset / Trial / NCT00511602

Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes

NCT00511602

Phase 2 Completed 123 enrolled Mannkind Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary objective to evaluate the effect of a 12-week treatment period with prandial administration of Technosphere Insulin on glucose control in subjects with T2 DM. Secondary objective is to Evaluate the safety and tolerability of a 12-week treatment period of Technosphere Insulin and Technosphere Placebo.

Timeline

Start
2003-12
Primary completion
2004-11
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Inhaled